Key result
Triple antiplatelet therapy was superior to dual antiplatelet therapy in decreasing 12-month major adverse cardiac events in obese patients undergoing coronary stenting.
Why the study?
Does triple antiplatelet therapy reduce major adverse cardiovascular events in obese patients undergoing coronary stenting compared to dual antiplatelet therapy?
RCT (n=428)
randomly assigned
Does triple antiplatelet therapy reduce major adverse cardiovascular events in obese patients undergoing coronary stenting compared to dual antiplatelet therapy?
Adding cilostazol to standard dual antiplatelet therapy reduces ischemic events without increasing major bleeding in obese patients undergoing coronary stenting.
Answers are grounded in this paper and cite their sources.
Supports triple antiplatelet therapy in obese patients after stenting; extends randomized DAPT evidence to this subgroup.
We evaluated the impact of triple antiplatelet therapy on platelet reactivity, reducing cardiovascular events and the safety in obese patients undergoing coronary stenting. Obese patients (n = 428) undergoing coronary stenting were randomly assigned to 2 groups: standard dual group (clopidogrel plus aspirin, n = 215) and triple group (n = 213); adjunctive cilostazol was added to the dual group treatment. Platelet reactivity was assessed at baseline and at 1-year follow-up by conventional aggregometry. Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up. At 1-year follow-up after stenting, major adverse cardiac events including death, myocardial infarction, and ischemic-driven TLR were lower in the triple group than the dual group. Major bleeding was similar in both the groups. In obese patients undergoing percutaneous coronary intervention, triple antiplatelet therapy was superior to dual antiplatelet therapy in decreasing thrombotic events in 12-month cardiac events, mainly driven by a decrease in the incidence of clopidogrel resistance.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2013) conducted an RCT in Obese patients undergoing coronary stenting (n=428). Triple antiplatelet therapy (clopidogrel, aspirin, cilostazol) vs. Dual antiplatelet therapy (clopidogrel plus aspirin) was evaluated on Major adverse cardiovascular events (death, myocardial infarction, and ischemic-driven TLR). Triple antiplatelet therapy was superior to dual antiplatelet therapy in decreasing 12-month major adverse cardiac events in obese patients undergoing coronary stenting.
Synapse has enriched 10 related papers. Consider them for comparative context: